New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Evidence-based Products

Functional Foods & Nutraceuticals' monthly digest of company-sponsored research in peer-reviewed journals

Study Claim: 3g EPA/d and 3g DHA/d (ROPUFA) increased systemic arterial compliance in 38 dyslipidemic men and women, resulting in reduced pulse pressure and total vascular resistance, effects that may reduce the risk of adverse cardiovascular events.

Published: Nestel P, et al. The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans. Am J of Clin Nutr 2002 Aug;76(2):326-30.

Abstract: Researchers explored whether n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (ROPUFA) improve systemic arterial compliance SAC (which reflects arterial elasticity) in dyslipidemic subjects. In a double-blind trial, they randomly tested 38 dyslipidemic subjects with 3g EPA/day, 3g DHA/day (ROPUFA), or a placebo for seven weeks, measuring arterial functions and plasma fatty acids at the beginning and end of the interventions.

Results showed that ROPUFA increased SAC—36 per cent with EPA and 27 per cent with DHA—compared with placebo. The major components contributing to the increase in SAC (systolic and pulse pressures and total vascular resistance) tended to decrease, but not significantly. Plasma total and VLDL triacylglycerol were significantly lower in the ROPUFA groups compared with placebo.

Potential Applications: ROPUFA is available in powder and liquid, in varying concentrations. The long-chain fatty acids have been shown to be beneficial in maternal nutrition, cardiovascular disease, depression (including postpartum) and diseases caused by inflammation.

More Info: Roche Vitamins Inc

Tel: +1 800 526 0189

Study Claim: In vivo investigation suggests that Remifemin (with black cohosh, Cimicifuga racemosa) does not stimulate cell proliferation and is safe for treating menopausal symptoms in women with a history of breast cancer.

Published: Freudenstein J, et al. Lack of promotion of estrogen-dependent mammary gland tumors in vivo by an isopropanolic Cimicifuga racemosa extract. Cancer Res 2002 Jun 15;62:3448-52.

Abstract: Researchers injected mammary tumors in Sprague Dawley rats with 7,12-dimethylbenz-[a]anthracene. Five to nine weeks later, they removed the animals' ovaries and administered daily doses of CR extract (.714, 7.14 or 71.4 mg/kg body weight) or 450 µg/kg/day mestranol; or CR vehicle/negative control).

Researchers analysed tumour number, size, plasma hormone levels and weight of estrogen-sensitive organs upon sacrificing the animals six weeks after the study began.

In contrast to mestranol treatment, CR treatment did not stimulate cancer growth. There were no differences in tumour number or size between the CR groups and the control group.

Prolactin, follicle-stimulating hormone, and luteinising hormone levels and organ weights and endometrial proliferation were unaffected.

More Info: Schaper & Bruemmer GmbH
Tel: +49 53 41 3070

AST Sports Science
Study Claim: 1.5g/kg body weight/day of VP2 100 per cent whey isolate protein supplement for 10 weeks was more effective at increasing muscle mass and strength and decreasing fat mass than casein protein in 13 resistance trained athletes.

Published: Cribb PJ, et al. The effect of whey isolate and resistance training on strength, body composition and plasma glutamine. Med Sci Sports Exerc 2002;34(5):168.

Abstract: Because few studies have examined which is the most effective dietary protein supplement for enhancing weight training exercise, researchers in this study compared whey isolate and casein.

In a randomised, double blind protocol, 13 resistance-trained males (ages 25 and 26) supplemented their normal diet with either VP2 whey isolate or casein (1.5g/kg body weight) daily for 10 weeks.

The VP2 group saw significantly greater gain in lean mass (4.99 ± .25kg) than the casein group (.81 ± .43kg). Although both groups significantly increased strength in the exercises, the VP2 group made greater strength increases in all three exercises compared with the casein group. The VP2 group also showed a significant decrease in fat mass (-1.46 ± .52kg), whereas the casein group exhibited a slight rise (.19 ± .27kg). Pre- and post-training plasma glutamine levels did not change in either group.

Researchers concluded that VP2 whey isolate supplementation was more effective at increasing muscle mass and strength and decreasing fat mass than casein protein supplementation in resistance trained athletes.

More Info: AST Sports Science
Tel: +1 800 627 2788
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.